[Latin Name] Panax ginseng CA Mey.

[Plant Source] Dried Root

[Specifications] Ginsenosides 10%–80%（UV）

[Appearance] Fine Light Milk Yellow Powder

[Particle size] 80 Mesh

[Loss on drying] ≤ 5.0%

[Heavy Metal] ≤20PPM

[Extract solvents] Ethanol

[Microbe]  Total Aerobic Plate Count: ≤1000CFU/G

Yeast & Mold: ≤100 CFU/G

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life]24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[What is Ginseng]

In terms of modern scientific research, ginseng is known to be an adaptogen. Adaptogens are substances that assist the body to restore itself to health and work without side effects even if the recommended dose is widely exceeded.

Ginseng due to its adaptogens effects is widely used to lower cholesterol, increase energy and endurance, reduce fatique and effects of stress and prevent infections.

Ginseng is one of the most effective antiaging supplements. It can alleviate some major effects of aging, such as degeneration of the blood system, and increase mental and physical capacity.

Other important benefits of ginseng is its support in cancer treatment and its effects on sports performance.

[Application]

1. Applied in food additives, it owns the effect of antifatigue, anti-aging and nourishing brain;

2. Applied in pharmaceutical field, it is used to treat coronary heart disease, angina cordis, bradycardia and high heart rate arrhythmia, etc.;

3. Applied in cosmetics field, it owns the effect of whitening, dispelling spot, anti-wrinkle, activating skin cells, making skin more tender and firm.

https://xangolover.com 520-226-1799

https://ernieg.themangosteenrevolution.com

A demonstration of how to take the Isotonix OPC-3 in the morning.
Category: Howto & Style
Tags:
Isotonix OPC-3 vitamins antioxidants allergy ailment relief anti-aging free radicals

Title: Pneumococcal infections and vaccination.
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia, Spain

OMICS International: https://omicsonline.org
Vaccine Conferences: https://conferenceseries.com/immunolog…
Global Medical Conferences: https://conferenceseries.com
Global Pharmaceutical Conferences: https://pharmaceuticalconferences.com
Global Cancer Conferences: https://cancersummit.org
Global Diabetes Conferences: https://diabetesexpo.com
Global Dental Conferences: https://dentalcongress.com
Global Nursing Conferences: https://nursingconference.com

Abstract
Pneumococci are major contributors to morbidity and mortality worldwide. They are the major cause of milder respiratory tract infections such as otitis and sinusitis, but also to more severe invasive infections such as community-acquired pneumonia with associated septicemia and meningitis. Even though being a devastating pathogen, pneumococci are also common colonizers of the upper respiratory tract of healthy children where from they may spread to cause disease. Risk groups for acquiring an invasive pneumococcal infection (IPD) include preschool children and the elderly, as well as immunocompromised individuals, splenectomised, and patients with a previous influenza virus infection. Several bacterial virulence factors have been described for pneumococci of which a major one is the capsular polysaccharide. Depending on differences in these capsular structures so far more than 90 different serotypes have been distinguished. Recently so called conjugated vaccines (PCV) have been introduced into the child hood vaccination program in many countries. These vaccines are based on a limited amount (7, 10 or 13) of the capsular serotypes. In Sweden PCVs were introduced in the whole of Sweden year 2009. Vaccine introduction has led to a reduction in the incidence of IPD in vaccinated children but also to serotype replacementand an increase of non-vaccine type disease.

Biography

Birgitta Henriques Normark is professor and head physician in Clinical microbiology at Karolinska Institute and Karolinska University hospital, as well as head physician at the Public Health Agency of Sweden. She is also vice dean for recruitment at Karolinska Institutet and a board member of the Swedish Research Council, Medicine and Health.Her research focuses on epidemiology, antibiotic resistance and host-microbe interactions in bacterial infections with special focus on pneumococcal epidemicity, molecular epidemiology, and mechanisms of invasive disease, innate immunity and host-microbe interactions determining disease outcome. The research has been published in 136 publications of which 107 are original peer reviewed articles.